ESMO 2017 Congress September 8-12, 2017 Madrid, Spain

Bild:©Lucia Uccellatore from Italy

Bild:©Lucia Uccellatore from Italy 

In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial for the organizer of ESMO 2017, that researchers and clinicians exchange knowledge.

According to the organizer the ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back. This exciting partnership creates a unique cancer congress in Europe with huge scientific reach and the true potential to improve the lives of cancer patients. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. Oncoletter ist proud presenting you some of the highlights of this years ESMO 2017 congress.

You will find data and comments on the following Practice-changing studies presented at ESMO 2017 at Oncoletter:

  • PACIFIC: new standard of care for locally advanced, unresectable stage III non-small-cell lung cancer (NSCLC).
  • IFCT-0302: questionned regular computed tomography (CT) scans in resected NSCLC.
  • COMBI-AD: new adjuvant treatment option for high-risk melanoma.
  • CheckMate 238: improved adjuvant therapy for patients with surgically resected stage III/IV melanoma at high risk of relapse.
  • LORELEI: greater tumour shrinkage in estrogen receptor positive and HER2 negative early breast cancer.
  • MONARCH 3: improved outcomes with a new initial strategy for postmenopausal women with hormone receptor positive, HER2 negative advanced breast cancer.
  • ARIEL 3: new maintenance therapy for recurrent ovarian cancer.
  • RANGE: promising treatment for advanced or metastatic urothelial cancer.
  • CheckMate 214: combination therapy reduces kidney cancer death risk.

Die Berichterstattung vom ESMO konnte dank Beiträgen zur Reise (Merck), Bannerwerbung (Medizin Medien Austria Verlag) und redaktionellen Auftragsarbeiten (Brustkrebs Deutschland e.V., Medical Tribune) realisiert werden. Alle in den Berichten gemachten Aussagen sind unabhängig vom Auftraggeber und auch unabhängig von Oncoletter gemacht worden.